OncoHub.ai
An abstract digest clustered by cancer type and ranked by clinical priority. Numerical results (HR, PFS, OS) are preserved; reliability caveats are embedded within each study's card.
Indication: EGFR exon20ins-mutated advanced NSCLC, 1L
Key finding: Sunvozertinib 300 mg/day vs carboplatin+pemetrexed; median PFS 10.3 vs 7.5 mo (HR 0.65, 95% CI 0.50–0.85, p=0.0008); ORR 58.9% vs 31.1%; median DoR 11.2 vs 7.1 mo; 90.2% crossover in the chemo arm.
Clinical relevance: Supports sunvozertinib as 1L therapy for EGFR exon20ins advanced NSCLC.
Source: ASCO Abstract LBA8500
Indication: Advanced ALK+ NSCLC, 1L
Key finding: Median PFS still not reached with lorlatinib (68.5–NR) vs 9.1 mo with crizotinib (HR 0.19, 0.13–0.26); 7-yr PFS 55% vs 3%; among patients event-free at 24 mo, 79% probability of 7-yr PFS; G3/4 AE 77% vs 57%.
Clinical relevance: Unprecedented long-term benefit sustained in ALK+ NSCLC.
Source: ASCO Abstract 8502
Indication: PD-L1+ (TPS ≥1%) advanced NSCLC, 1L
Key finding: PFS HR 0.35 (0.26–0.47; p<0.0001), median not reached vs 5.7 mo; ORR 70.2% vs 42.0%; OS HR 0.55 (0.36–0.85, immature); ≥G3 TEAE 55.3% vs 31.4%.
Clinical relevance: First Phase 3 PFS benefit for a TROP2-targeted ADC + IO combination in PD-L1+ NSCLC.
Source: ASCO Abstract 8506
Indication: EGFR/ALK/ROS1 wild-type metastatic non-squamous NSCLC, 1L
Key finding: Control arm tislelizumab; median PFS 14.42 (12.35–NE) vs 8.34 (6.97–12.39) mo; HR 0.67 (0.52–0.86; P=0.0017); ≥G3 TRAE 56.4% vs 48.7%.
Clinical relevance: A new potential 1L option; OS data awaited.
Source: ASCO Abstract LBA8507
Indication: RET fusion-positive advanced NSCLC, 1L
Key finding: Median PFS 18.7 vs 9.0 mo (P=0.003); ORR 65.5% vs 41.6% (P<0.001); median DoR 20.6 vs 9.7 mo. However OS HR 1.09 (P=0.742); infections 71.3% (including pneumonia 19.4%) vs 51.9%; 8 infection-related deaths (7.4%) vs 0.
Clinical relevance: Effective but requires infection monitoring.
Source: ASCO Abstract 8504
Indication: Atypical EGFR-mutated advanced NSCLC, 1L
Key finding: At 31.3-mo median follow-up, median OS 41.0 mo (27.7–NE); 3-yr OS 55%; 4-yr OS 46%; 20% still on 1L therapy. SC formulation available.
Clinical relevance: Long-term benefit in atypical EGFR.
Source: ASCO Abstract 8501
Indication: Pretreated (including lorlatinib) and TKI-naïve ALK+ NSCLC
Key finding: TKI-pretreated ORR 31%; in G1202R mutation ORR 68%; IC-ORR 32%; in the 1L (TKI-naïve) cohort ORR 86% (n=44), IC-ORR 78%.
Clinical relevance: Effective including post-lorlatinib; TRK-sparing safety profile.
Source: ASCO Abstract 8503
Indication: Oncogene-mutant NSCLC, asymptomatic brain metastases
Key finding: 2-yr cumulative incidence of IC progression 21.7% vs 50.0% (sub-HR 0.35, P<0.001); median icPFS 18 vs 14.3 mo (P=0.35); no OS difference (23.3 vs 28.7 mo, P=0.06).
Clinical relevance: Upfront RT reduced IC progression, but a survival benefit has not yet been shown.
Source: ASCO Abstract 8624
Indication: Advanced RET fusion-positive NSCLC
Key finding: Pretreated ORR 87.1% (77.0–93.9), mPFS 27.5 mo; treatment-naïve ORR 81.3%, mPFS not reached; with CNS metastases ORR 82.6% and 75.0%; G≥3 TRAE 40.5%.
Clinical relevance: High activity in both TKI-naïve and pretreated settings.
Source: ASCO Abstract 8505
Indication: RRMM, anti-CD38 mAb + lenalidomide-exposed
Key finding: Median PFS 18.0 vs 8.3 mo (HR 0.48, P<0.0001); ORR 80.2% vs 53.4%; ≥CR 26.7% vs 8.9%; G3-4 neutropenia 61.1% vs 9.1%, infections 34.0% vs 15.6%.
Clinical relevance: The mezigdomide combination is a potential new SOC in early-relapse RRMM.
Source: ASCO Abstract LBA7506
Indication: RRMM, 1–3 prior LOTs (anti-CD38 + LEN-exposed)
Key finding: PFS HR 0.29 (0.23–0.38, P<0.0001); 18-mo PFS 69.8% vs 26.9%; OS HR 0.60 (P=0.0020); ≥CR 65.9% vs 16.8%; CRS 66.0% (mostly G1/2); G3/4 infections 41.6% vs 29.0%.
Clinical relevance: Teclistamab is a new SOC candidate in early-relapse RRMM.
Source: ASCO Abstract 7507
Indication: Newly diagnosed Mayo IIIa/IIIb AL amyloidosis
Key finding: The primary hierarchical ACM+CVH endpoint was not met in the overall population (win ratio 1.1, P=0.332). In the κ isotype, ACM HR 0.38 (0.17–0.86; nominal P=0.012), CVH rate ratio 0.29 (nominal P=0.028); no difference in the λ isotype.
Clinical relevance: A potential first-in-class anti-fibril mAb option for κ AL amyloidosis.
Source: ASCO Abstract 7501
Indication: Transplant-eligible newly diagnosed MM (TE-NDMM)
Key finding: 35% high-risk by the new CGS. MRD-neg (10⁻⁶): standard-risk 67% vs 39% (P=0.0001), high-risk 56% vs 26% (P=0.0003); PFS HR standard-risk 0.38 (P=0.001), high-risk 0.54 (P=0.039).
Clinical relevance: DVRd is supported as SOC irrespective of cytogenetic risk.
Source: ASCO Abstract 7505
Indication: TE-NDMM
Key finding: Sustained MRD-neg ≥3 yrs vs <3 yrs: 7-yr PFS 84.7% vs 35.4% (HR 0.16), 7-yr OS 97% vs 69% (HR 0.08); 5-yr sustained MRD-neg → 7-yr PFS 91%.
Clinical relevance: Long-duration sustained MRD-neg is required in high-risk patients.
Source: ASCO Abstract 7504
Indication: High-risk smoldering MM (early intervention)
Key finding: Monotherapy ORR 92%, ≥VGPR 82%, ≥CR 45%; 9-mo PFS 95%, OS 100%; CRS G1/2 66%/4% (G3 in 2 patients), no ICANS; G3-4 infections 14%.
Clinical relevance: An active and feasible option for early intervention in HR SMM.
Source: ASCO Abstract 7500
Indication: Transplant-ineligible newly diagnosed MM
Key finding: ORR ≥83% across all cohorts; high induction dose intensity (SHORT+STRETCH) ≥CR/MRD-neg 75/55% vs 59/43%; ≥G2 ophthalmic findings 90% vs 69%; G3/4 ocular 79% vs 35%.
Clinical relevance: High induction + low maintenance dose intensity is the optimal balance.
Source: ASCO Abstract 7503
Indication: RRMM, prior BCMA-targeted therapy-exposed
Key finding: All prior-BCMA ORR 47% (17/36); prior CAR-T group ORR 50%; BCMA-directed last LOT ORR 58%; median DoR 13 mo; CRS G1/2 (one G3 ICANS); G3/4 neutropenia 36%, infections 41%.
Clinical relevance: Response to sequential anti-BCMA therapy is possible; administrable without step-up dosing.
Source: ASCO Abstract 7508
Indication: R/R systemic AL amyloidosis
Key finding: hOR 100% (80 mg), 92.3% (240 mg); ≥hCR 57.1% and 38.5%; iFLC <20 mg/L 100% and 84.6%; CRS G1/2 50%, no ICANS; median time to hCR ~3 weeks.
Clinical relevance: Rapid, deep hematologic response; will support a Phase 2.
Source: ASCO Abstract 7502
Indication: Previously untreated locally advanced/metastatic urothelial carcinoma (la/mUC), 1L
Key finding: EV+P vs chemo median OS 33.6 vs 15.9 mo; 42-mo OS 44.0% vs 24.6%; HR 0.53 (0.45–0.63); CR rate 45.1% vs 32.8%; 66.2% of those reaching CR converted from a prior PR.
Clinical relevance: Sustained OS benefit; the impact of treatment duration on outcome was emphasized.
Source: ASCO Abstract 4507
Indication: Muscle-invasive bladder cancer (MIBC), perioperative
Key finding: Central pCR 65% (26/40), PaR 80%; pCR 55% including all patients; 1-yr EFS 88%, OS 95%; G3/4 TRAE (chemo) 38%/17%.
Clinical relevance: Integrating rBCG + chemo-IO yields high pCR in MIBC; promising for bladder-preserving approaches.
Source: ASCO Abstract 4503
Indication: Adjuvant after high-risk MIBC
Key finding: 12-mo HRQOL changes showed no statistically or minimally clinically meaningful difference between arms.
Clinical relevance: The adjuvant pembrolizumab DFS benefit was achieved without compromising quality of life.
Source: ASCO Abstract 4513
Indication: MIBC, perioperative
Key finding: In 27 patients with RC+PLND, pCR 48.1% (28.7–68.1); pathological downstaging 59.3%; G≥3 AE 40.5%; no patient lost surgical eligibility.
Clinical relevance: Potential even in cisplatin-ineligible patients; supports a Phase 3.
Source: ASCO Abstract 4506
Indication: Locally advanced/metastatic urothelial carcinoma
Key finding: In the 2.4–4.8 mg/kg cohort (AS ≥0.5) ORR 48% (10/21); EV-pretreated ORR 40%, EV-naïve 67%; median DoR 7 mo; low CYP2D6 activity score associated with DLT.
Clinical relevance: May be an option after EV resistance; CYP2D6-based dosing optimization ongoing.
Source: ASCO Abstract 4508
Indication: dMMR/MSI-H advanced/recurrent endometrial cancer
Key finding: At 55.6-mo median follow-up, 4-yr PFS 57.9% vs 15.7%; mixture-cure model "cure" rate 54% (95% CI 35–72%).
Clinical relevance: Durable disease control and potential cure for a substantial fraction of patients.
Source: ASCO Abstract 5501
Indication: Advanced/recurrent EC, dMMR and pMMR cohorts
Key finding: dMMR: 48-mo OS 80% vs 60% (HR 0.53); pMMR: median OS 46.9 vs 35.1 mo (HR 0.84); benefit persisted despite high post-study ICI use in the placebo arms (dMMR 55%, pMMR 57%).
Clinical relevance: Adding pembrolizumab is supported irrespective of MMR status.
Source: ASCO Abstract 5502
Indication: Platinum-resistant ovarian cancer (PROC)
Key finding: Median OS 16.0 vs 11.9 mo; HR 0.65 (0.51–0.83; P=0.0004); benefit independent of prior taxane use.
Clinical relevance: A new potential option in PROC.
Source: ASCO Abstract 5503
Indication: Platinum-resistant/refractory ovarian cancer
Key finding: Median PFS 4.57 vs 2.69 mo (HR 0.427, P<0.001); no median OS difference (12.09 vs 12.12 mo, P=0.583); OS benefit in the subgroup not receiving subsequent therapy (HR 0.599, P=0.016).
Clinical relevance: PFS benefit, including in those with prior anti-angiogenic therapy.
Source: ASCO Abstract LBA5504
Indication: FRα-high platinum-eligible recurrent ovarian cancer
Key finding: Carboplatin+MIRV→MIRV vs carboplatin-based doublet+PARPi maintenance; median PFS 9.53 vs 9.79 mo (HR 1.00, P=0.996). Primary endpoint not met.
Clinical relevance: In this setting the carboplatin+MIRV combination provided no benefit.
Source: ASCO Abstract 5506
Indication: Advanced ovarian cancer (stage IIIB-IVA)
Key finding: Surgery after 3 vs 6 NAC cycles; median DFS 20.2 vs 23.4 mo (HR 0.88, P=0.48); CC0 83.2% vs 90%; major postop complications 5% vs 11% (P=0.11).
Clinical relevance: Delayed surgery showed no DFS benefit; further studies needed.
Source: ASCO Abstract 5505
Indication: Recurrent/metastatic cervical cancer
Key finding: At the 2.4 mg/kg RP2D, cORR 29.3%, DCR 78.0%, mPFS 6.7 mo (3.5–12.1), mDoR 9.0 mo; G≥3 anemia 15.9%, WBC decrease 25.0%.
Clinical relevance: Promising activity in heavily pretreated patients.
Source: ASCO Abstract 5507
Indication: Recurrent/metastatic cervical cancer
Key finding: Unconfirmed ORR 22.2% (2.7 mg/kg; 4/18), 37.5% (3.6 mg/kg; 6/16); one confirmed CR (2.7 mg/kg).
Clinical relevance: A safety advantage versus other MMAE-based therapies; longer follow-up awaited.
Source: ASCO Abstract 5508
Indication: RCC with bone metastases
Key finding: Stratified SSE-FS median 17.9 vs 17.6 mo (HR 1.24); OS 32.2 vs 21.3 mo (HR 0.77, 0.42–1.41); primary endpoint not met, futility boundary crossed.
Clinical relevance: No role for radium-223 in RCC; alternative radiotherapeutics should be investigated.
Source: ASCO Abstract 4500
Indication: Adjuvant high-risk ccRCC
Key finding: Low baseline ctDNA positivity (16-plex 5.4%, 64-plex 8.2%); in both arms ctDNA positivity negatively associated with DFS (P<0.05); low sensitivity (16-plex 12%), high specificity (98–99%); higher ctDNA clearance in the pembro arm.
Clinical relevance: Current ctDNA assays are limited in ccRCC; pembrolizumab increases clearance.
Source: ASCO Abstract 4502
Indication: Advanced non-clear cell RCC, 1L
Key finding: ORR 51.6% (16/31); DCR 96.8%; median PFS 16.7 mo (11.8–NR); total cohort mPFS 17.3 mo; G≥3 TRAE 58.1%.
Clinical relevance: Encouraging activity in nccRCC; Phase Ib RP2D 10 mg/kg.
Source: ASCO Abstract 4501
Indication: Follicular lymphoma (FL)
Key finding: ORR 87%, CRR 72%; 18-mo PFS 56%, OS 92%; CRS 34% (no ≥G3), ICANS 3%.
Clinical relevance: Supports the real-world efficacy/safety of bispecifics.
Source: ASCO Abstract 7010
Indication: DLBCL (LymphoMAP molecular classification)
Key finding: In the FMAC subgroup, Pola-R-CHP PFS HR 0.66 (0.43–1.01), OS HR 0.64 (0.37–1.10); the PFS trend favored pola across all subgroups.
Clinical relevance: Potential for molecular subtype-based patient selection.
Source: ASCO Abstract 7017
Indication: Aggressive B-cell lymphoma
Key finding: At the 0.4 mg dose, EOT CMR 82%, 12-mo PFS 96%; MRD-neg 83% (PhasED-Seq).
Clinical relevance: Deep-response signal; larger studies needed.
Source: ASCO Abstract 7011
Indication: R/R T-ALL and T-NHL
Key finding: 100% CR in T-ALL (5/5); ORR 66.7% in T-NHL; G3-5 events 33% including EBV reactivation (55.6%).
Clinical relevance: A CAR-T signal in T-cell malignancies; toxicity monitoring is critical.
Source: ASCO Abstract 7015
Indication: R/R DLBCL
Key finding: Variable safety/efficacy across 4 patients; one patient experienced G3 CRS/HLH and a fatal infection.
Clinical relevance: Allogeneic CAR-T proof of concept; safety signals must be closely monitored.
Source: ASCO Abstract 7013
Key finding: Telepalliative care within ≤7 days of death was associated with home death (OR 5.93, P=0.004); reduced ICU admission (OR 0.34, P=0.006).
Clinical relevance: A tangible effect of remote palliative support in end-of-life care.
Source: ASCO Abstract 1518
Key finding: With group CHW-led ACP education, at 6 months ACP documentation 100% vs 40%, hospice use 55.6% vs 10.0%.
Clinical relevance: A scalable ACP model that improves access.
Source: ASCO Abstract 1521
Key finding: The digital app reduced fatigue (40.6 vs 37.6, p=0.012) and depressive symptoms (2.5 vs 3.4, p=0.044); no difference in QOL.
Clinical relevance: A scalable, accessible supportive-care intervention in multiple myeloma.
Source: ASCO Abstract 1513
Key finding: LLM-generated SIC summaries were 96.4% accurate; preliminary 90-day data showed a trend toward reduced health-care utilization in the intervention arm.
Clinical relevance: Feasibility of using LLMs in clinical documentation.
Source: ASCO Abstract 1519
Key finding: With Q6-weekly pembrolizumab + telehealth, health-care days 8.5 vs 12.0 (P=0.14, nonsignificant); steroid-requiring irAEs similar (25% vs 27%).
Clinical relevance: Extended dosing + telehealth is feasible; the primary outcome was nonsignificant.
Source: ASCO Abstract 1515
Key finding: EoL quality indicators were suboptimal versus US benchmarks; chemotherapy within 30 days of death 24%.
Clinical relevance: Need for EoL quality improvement in low-resource settings.
Source: ASCO Abstract 1517
This report was generated automatically and is not medical advice. Clinical decisions must be verified against official abstract/presentation full texts and current guidelines.
OncoHub.ai · ASCO 2026 Gündem
Bu içerik editoryaldir. Tıbbi tavsiye değildir. Klinik karar hekime aittir.
oncohub.ai →